Orthogen Autologous Conditioned Serum: An Update of the currently published Clinical Studies

Orthogen Autologous Conditioned Serum is a proven non-recombinant autobiological therapeutic for local treatment of pain, inflammation and tissue injury, functional both in humans and animals. Unlike other autobiologics, Orthogen-ACS stands out wielding the full spectrum of mediators released from all cells present in whole blood, the blood cell secretome. Through a process of extended coagulation of whole blood, Orthogen-ACS contains a unique composition of mediators including but not limited to growth factors, cytokines, lipid mediators, mitochondrial derived peptides and extracellular vesicles. Release of these mediators is triggered by the “tissue” blood when artificially confronted with the tasks Stop bleeding, Fend off pathogens and Initiate healing. The clinical effectiveness of local injection treatment with Orthogen-ACS has been shown in a multitude of clinical indications incl. osteoarthritis, radiculopathy, tendinopathy, muscle strain, ligament, meniscal tear, wound healing and others. This review reports on the 44 published human clinical studies dating from early 2000 until recent. Several of these publications report small case number; however, strong clinical evidence exists for knee osteoarthritis, followed by lower back pain and radiculopathy. This broad spectrum of indications suggests that ACS mode of action has profoundly regenerative and immune-modulating properties. In conclusion, ACS therapy is efficacious, safe, simple to process. Orthogen-ACS appears to activate a wide variety of pathways that converge on the attempt of tissue repair and regeneration.